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Abstract
Background: Fatty acid-binding protein 4 (FABP4/A-FABP/aP2), a lipid chaperone, is expressed in both adipocytes and
macrophages. Recent studies have shown that FABP4 is secreted from adipocytes and that FABP4 level is associated with
obesity, insulin resistance, and atherosclerosis. However, little is known about the impact of FABP4 concentrations on
prognosis. We tested the hypothesis that FABP4 level predicts prognosis of patients with end-stage renal disease (ESRD), a
group at high risk for atherosclerosis-associated morbidity and mortality.
Methods and Results: Biochemical markers including FABP4 were determined in 61 ESRD patients on chronic hemodialysis
(HD). Serum FABP4 level in females (404.2630.5 ng/ml) was significantly higher than that in males (315.8630.0 ng/ml), and
the levels in ESRD patients were about 20-times higher than those in age-, gender- and body mass index (BMI)-matched
control subjects with normal renal function. FABP4 level was decreased by 57.2% after HD and was positively correlated
with blood pressure, BMI, and levels of lipids and insulin. Multiple regression analysis indicated that HD duration, BMI, and
triglycerides level were independent determinants for FABP4 level. ESRD patients with high FABP4 levels had higher
cardiovascular mortality during the 7-year follow-up period. Cox proportional hazard regression analysis showed that
logarithmically transformed FABP4 level was an independent predictor of cardiovascular death adjusted for age, gender, HD
duration, BMI, and triglycerides level (hazard ratio, 7.75; 95% CI, 1.05–25.31).
Conclusion: These findings suggest that FABP4 level, being related to adiposity and metabolic disorders, is a novel predictor
of cardiovascular mortality in ESRD.
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Introduction
Intracellular lipid chaperones known as fatty acid-binding proteins
(FABPs) are a group of molecules that coordinate lipid responses in
cells [1]. FABPs are abundantly expressed 14–15 kDa proteins that
can reversibly bind to hydrophobic ligands, such as saturated and
unsaturated long chain fatty acids, eicosanoids, and other lipids, with
high affinity[1]. FABPs have been proposed to facilitate the transport
of lipids to specific compartments in the cell, such as to the lipid
droplet for storage, to the endoplasmic reticulum for signaling,
trafficking, and membrane synthesis, to the mitochondria or pero-
xisome for oxidation, to cytosolic or other enzymes to regulate their
activity, and to the nucleus for lipid-mediated transcriptional re-
gulation. One of the FABPs, fatty acid-binding protein 4 (FABP4),
known as adipocyte FABP (A-FABP) or aP2, is expressed in both
adipocytes and macrophages and plays important roles in the
regulationofinsulinsensitivityand thedevelopmentofatherosclerosis
[2–8]. Therefore, it is expected that modification of FABP4 function
will provide a new class of therapeutic agents. In fact, we recently de-
monstrated that chemical inhibition of FABP4 could be a therapeutic
strategy against insulin resistance, diabetes mellitus (DM), fatty liver
disease, and atherosclerosis in experimental models[9].
In the present study, we hypothesized that serum FABP4 is a
novel marker for risk stratification of end-stage renal disease
(ESRD) patients on hemodialysis (HD). The rationale for this
hypothesis is four-fold. First, it has been shown that FABP4 is
secreted from adipocytes [10], although there is no typical
sequence of secretory signal peptides. At least, we previously
confirmed that FABP4 release from adipocytes was not an escape
due to apoptosis or necrosis of adipocytes [7]. Second, recent
studies have shown that elevation of serum FABP4 is associated
with obesity and insulin resistance, risk factors of atherosclerosis,
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27356and carotid atherosclerosis [10–13]. Third, chronic kidney disease
has been shown to be a risk factor of atherosclerosis [14]. Fourth,
atherosclerotic vascular diseases are a major cause of death in
ESRD patients [14].
Methods
Ethics statement
This study was performed with the approval of the institutional
ethical committee of Sapporo Medical University, and written
informed consent was received from all of the subjects.
Participants
Sixty-one HD patients (31 males and 30 females) aged 39–78
years (mean age: 61.661.8 years, mean6SEM) were recruited. All
of the patients had anuria or oliguria (urine volume ,200 ml/
day). None of the patients had a history of acute myocardial
infarction within 6 months prior to the start of this study, chest
pain at rest or in the peridialysis period, unstable hemodynamics
during dialysis, critical illness, or a history of recent major vascular
surgery. The mean duration of HD was 63.467.1 months. The
underlying renal diseases of the HD patients were diabetes mellitus
(n=21), glomerulonephritis (n=22), nephrosclerosis (n=6) and
other diseases (n=12). Diabetic patients treated with thiazolidi-
nediones, PPARc agonists, were excluded because the FABP4 ge-
ne is known as a target of PPARc. All HD patients were dialyzed 2
or 3 times per week on Monday-Wednesday–Friday, Tuesday–
Thursday–Saturday, or Tuesday–Satur day using high-flux mem-
branes (dialysis filter surface area, 1.1– 2.1 m
2). Sixty-one age-,
gender- and body mass index-matched control subjects (31 men
and 30 women; mean age, 61.262.0 years) who had been taking
no medication were also enrolled to compare FABP4 levels be-
tween subjects with and without renal dysfunction. None of the
control subjects had any evidence of complications such as endo-
crine or metabolic disturbances, cerebrovascular or cardiovascular
disease, and renal disease.
Measurement of biochemical markers
Blood samples in HD patients were drawn before the start and
at the end of a routine HD treatment on Monday or Tuesday.
Assays of FABP4 (ng/ml) were per-formed using blood samples
taken before and after HD. Other biochemical assays, such as
assays of total protein, creatinine, blood urea nitrogen, lipid vari-
ables, glucose, insulin, and adiponectin, were performed using
blood samples taken before hemodi-alysis. Serum FABP4 level was
measured using a commercially available enzyme-linked immu-
nosorbent assay kit (Biovendor R&D, Mordrice, Czech Republic).
The accu-racy, precision and reproducibility of this kit have been
described previously [10]. Plasma glucose was determined by the
glucose oxidase method. Plasma insulin was measured by a ra-
dioimmunoassay method (Insulin RIA bead, Dianabot, Tokyo,
Japan). Serum lipid profiles, including total cholesterol, high-
density lipoprotein (HDL)-cholesterol and triglycerides, were esti-
mated by enzymatic methods. Serum adiponectin level was
measured using a commercially available sandwich enzyme-linked
immunosorbent assay kit (Otsuka Pharmaceuticals Co., Ltd.,
Tokushima, Japan).
Statistical analysis
Numeric variables are expressed as means6SEM. The Mann-
Whitney U test was used for comparisons between two unpaired
variables.Thedifferencebetweentwopairedvariableswasanalyzed
by the Wilcoxon signed rank test. Group statistical comparisons
were assessed by the chi-square test. Before performing regression
analyses, the distribution of each parameter was testedfor normality
using the Shapiro-Wilk W test, and non-normally distributed
parameters were logarithmically transformed. Simple linear regres-
sion analysis was used to determine the correlation between two
variables. Multiple linear regression analysis was used to identify
independent determinants of the FABP4 concentrations and the
percentage of variance in the FABP4 concentrations that they
explained (R
2). Receiver operating characteristic (ROC) analysis
was performed to determine the inflection point at which the
FABP4 level provided the most sensitive prediction of cardiovas-
cular death as a result of sudden cardiac death/arrhythmia, heart
failure, atherothrombotic events (myocardial infarction, stroke,
mesenteric ischemia). For a given FABP4 level, the ordinate value
shows the percentage of patients with that FABP4 level who died
(true-positive rate or sensitivity), and the abscissa value shows the
percentage of patients with that FABP4 level who did not die (false-
positive rate or 1-specificty). Using the ROC-derived optimal cutoff
value, patients were divided into two groups. Survival rate was
analyzed by log-rank tests of Kaplan-Meier curves in the two
groups. Cox regression analyses were performed for cardiovascular
death as an end point. A p value of ,0.05 was considered sta-
tistically significant. All data were analyzed by using JMP 8 for
Macintosh (SAS Institute, Cary, NC).
Results
FABP4 levels in hemodialysis patients
The FABP4 level in HD males were significantly lower than that
in HD females (Figure 1A; males vs. females: 315.8630.0 vs.
404.2630.5 ng/ml), and these levels were about 20-times higher
than those in both male and female controls with normal renal
function (Figure 1B; males vs. females: 16.061.7 vs. 20.561.6 ng/
ml). After HD, the FABP4 level was significantly decreased by
57.2% (before vs. after: 359.3622.0 vs. 153.9610.5 ng/ml) but
was still higher than that in control subjects (Figure 1C).
Simple and multiple regression analyses for FABP4
In all of the HD patients, FABP4 levels were positively cor-
related with HD duration, body mass index, waist circumference,
blood pressures, and levels of total cholesterol, LDL-cholesterol,
triglycerides, and insulin and were negatively correlated with levels
of HDL-cholesterol and adiponectin (Table 1). Multiple regression
analysis for predicting FABP4 level was performed using the
correlated and nonconfounding parameters, such as age, gender,
HD duration, body mass index as an index of adiposity, systolic
blood pressure, and levels of triglycerides as a lipid profile, insulin,
and adiponectin. The result revealed that HD duration, body mass
index, and level of triglycerides were independent predictors for
FABP4 level, explaining a total of 55% of the variance in this
measure (R
2=0.55) (Table 2).
Predictor of cardiovascular mortality in ESRD
During the 7-year follow-up period, we confirmed 13 out of 61
patients who died of cardiovascular events. ROC analysis of the
correlation between FABP4 levels in HD patients and the occur-
rence of cardiovascular death was performed. We chose the inflec-
tion point as the optimal cutoff value, 364.1 ng/ml (Figure 2A;
sensitivity: 76.9%, specificity: 68.8%, area under the curve: 0.70).
Using the cutoff point, HD patients were divided into two groups:
Low-FABP4 (HD patients with FABP4 levels below the point) and
High-FABP4 (HD patients with FABP4 levels above the cutoff)
groups. During the 7-year follow-up period, 3 out of 36 Low-
FABP4 patients and 10 out of 25 High-FABP4 patients died of
cardiovascular events. Kaplan-Meier survival curves showed that
Serum FABP4 Level Predicts Cardiovascular Events
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did the Low-FABP4 patients (Figure 2B).
Clinical characteristics of the HD patients split by the two groups
are shown in Table 3. There were no significant inter-group differences
in age, gender, presence of DM, blood pressure, and Kt/V as an index
of dialysis adequacy. Drug therapies including administration of
antihypertensive drugs and statins were comparable in the Low-
FABP4 and High-FABP4 groups. Body mass index and waist
circumference were significantly higher in the High-FABP4 patients
than in the Low-FABP4 patients. The High-FABP4 patients had
significantly higher levels of total cholesterol, triglycerides, and insulin
and lower levels of adiponectin than did the Low-FABP4 patients. No
significant differences were found in other parameters, including serum
total protein, blood urea nitrogen, creatinine, potassium, and C-
reactive protein, between the Low-FABP4 and High-FABP4 groups.
Cox proportional hazard regression analysis for predicting car-
diovasculardeathwasperformed includingFABP4level,age,gender,
presence of DM, and the independent determinants of FABP4 level
(HD duration, body mass index, and level of triglycerides) in the
multiple regression analysis (Table 2) which also have a significant
difference between the Low-FABP4 and High FABP4 groups
(Table 3). The result demonstrated that FABP4 concentration was
a significant explanatory variable after adjustment of the other
parameters, suggesting that FABP4 level was an independent
predictor of long-term cardiovascular mortality (Table 4).
Figure 1. Concentrations of FABP4. FABP4 levels were investigated in the males and females of hemodialysis patients (A) and control subjects
with normal renal function (B). FABP4 levels were determined before and after hemodialysis (C). Values are presented as means6SEM. *P ,0.05.
doi:10.1371/journal.pone.0027356.g001
Table 1. Simple regression analysis for log FABP4.
rp
Age 20.175 0.178
HD duration 0.253 0.049
Body mass index 0.315 0.013
Waist circumference 0.345 0.012
Systolic blood pressure 0.259 0.043
Diastolic blood pressure 0.325 0.011
Total cholesterol 0.378 0.004
LDL cholesterol 0.291 0.024
HDL cholesterol 20.256 0.046
Triglycerides 0.506 ,0.001
Insulin 0.430 0.002
Adiponectin 20.366 0.004
doi:10.1371/journal.pone.0027356.t001
Table 2. Multiple regression analysis for log FABP4.
tp
Age 0.118 0.907
Gender (Male) 21.280 0.207
HD duration 4.215 ,0.001
Body mass index 2.320 0.025
Systolic blood pressure 0.192 0.849
Triglycerides 3.277 0.002
Insulin 0.563 0.576
Adiponectin 21.651 0.106
R
2=0.55
doi:10.1371/journal.pone.0027356.t002
Serum FABP4 Level Predicts Cardiovascular Events
PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e27356Discussion
To the best of our knowledge, this is the first report on the
impact of elevation of circulating FABP4 concentrations on long-
term prognosis of ESRD. Previous studies using animal models
indicate that FABP4 plays a significant role in several aspects of
metabolic syndrome, including insulin resistance, type 2 DM and
atherosclerosis, through its action at the interface of metabolic and
inflammatory pathways in adipocytes and macrophages [1–8]. In
a human study, reduced expression of FABP4 in adipose tissue was
suggested to have beneficial effects on cardiovascular and
metabolic health [15]. Subjects with a genetic variation of the
FABP4 locus (T-87C) leading to decreased FABP4 expression in
adipose tissue showed lower levels of triglycerides as well as a
significantly reduced risk for cardiovascular disease. Taken
together, these observations support the notion that measurement
of FABP4 concentration is useful for risk stratification and for
guiding treatment in observational or interventional studies.
However, it is clearly necessary to prospectively evaluate whether
a change in the FABP4 value indeed reflects conditions of
metabolic syndrome and atherosclerosis and predicts long-term
cardiovascular outcomes in patients regardless of ESRD.
Figure 2. Receiver operating characteristic (ROC) analysis and Kaplan-Meier survival curve. (A) ROC analysis of the correlation between
FABP4 levels in HD patients and the occurrence of cardiovascular death is shown. The ordinate values show the corresponding true-positive rate
(fraction of patients with that FABP4 level who died) and the abscissa values show the corresponding false-positive rate (fraction of patients with that
FABP4 level who did not die). The inflection point (indicated by X) was chosen as the optimal cutoff value, 364.1 ng/ml (sensitivity: 76.9%, specificity:
68.8%, area under the curve [AUC]: 0.70). (B) According to the cutoff point of FABP4 level, HD patients were divided into two groups: Low-FABP4 and
High-FABP4 groups, and Kaplan-Meier curves for cardiovascular death are analyzed in the two groups. Broken lines (Low-FABP4 group), patients with
FABP4 levels of ,364.1 ng/ml (n=36, 22 males and 14 females); Solid lines (High-FABP4 group), patients with FABP4 levels of $364.1 ng/ml (n=25, 9
males and 16 females). Survival rates were compared by log-rank test. *P ,0.05.
doi:10.1371/journal.pone.0027356.g002
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being higher in females than in males as previously reported [10–
13,16]. However, multiple regression analysis showed that gender
was not a significant determinant of FABP4 concentration in HD
patients. FABP4 level was significantly higher in HD patients than
in the controls, which is consistent with previous findings in patients
with renal dysfunction [16–18]. In the control subjects, FABP4
levels were negatively correlated with estimated glomerular
filtration rate (data not shown), which is an index of renal function,
as previously reported in DM patients with nephropathy [16]. We
previously measured concentrations of FABP3, which is another
member of the FABP family known as heart-type FABP (H-FABP),
in HD patients [19]. We found the concentration of FABP3 was
increased 13.8-fold in HD patients compared to that in control
subjects with normal renal function and was reduced by 40% after
HD but was still higher than that in control subjects. Those results
are similar to the results of the present study. The molecular weights
of FABP3 and FABP4 are almost the same, about 15 kD. It is
expected that the sieving effects of HD dialyzers on these two
proteins are similar. These findings suggest that renal elimination is
a major route by which physiological levels of FABPs are main-
tained. Interestingly, similar mechanisms of elimination have been
proposed for other adipocyte-derived factors, such as leptin,
adiponectin, and retinol-binding protein 4 [20–22]. Taking these
into consideration, FABP4 appears to be accumulated in circulation
due to diminished renal excretion in chronic kidney disease.
Recent studies have demonstrated an association between
increased FABP4 levels and metabolic parameters even in HD
patients [17,18]. In the present study, we confirmed that FABP4
levels were significantly correlated with adiposity, blood pressure,
insulin resistance, and dyslipidemia in HD patients. Furthermore,
body mass index and triglycerides were independent predictors for
FABP4 concentration, and this relationship was independent of
HD duration, suggesting that a high level of FABP4 is attributable
to metabolic syndrome even in patients with ESRD. Strikingly,
FABP4 level was an independent predictor of cardiovascular death
after adjustment of metabolic parameters.
One limitation in this study is the small number of patients
enrolled. As another limitation, we did not directly assess the
extent of atherosclerosis in each patient. Thus, the relationship
between FABP4 level and progression of atherosclerosis remains
unclear. These issues warrant further investigation in a prospective
study recruiting a larger number of patients.
In conclusion, concentration of serum FABP4 may be not only a
marker of metabolic syndrome that can be used even for ESRD
patients but also a novel predictor of cardiovascular mortality in
patients at high risk of atherosclerotic cardiovascular events.
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Table 3. Basal and biochemical characteristics of 61 patients.
Whole Low-FABP4 High-FABP4
n 6 13 62 5
Male/Female 31/30 22/14 9/16
Age (years) 61.661.8 62.662.3 60.262.8
Diagnosis
Diabetes mellitus 21 12 9
Glomerulonephritis 22 10 12
Nephrosclerosis 6 6 0
Others 12 8 4
HD duration (months) 63.467.1 51.469.0 80.6610.8*
Body mass index (kg/m
2) 21.460.5 20.760.6 22.460.4*
Waist
circumference (cm)
78.061.5 75.362.0 81.462.3*
Systolic blood pressure
(mmHg)
140.062.9 137.463.8 143.764.5
Diastolic blood pressure
(mmHg)
77.061.8 74.062.3 80.462.7
Kt/V 1.4460.05 1.4260.06 1.4560.08
Drug therapy
ACE inhibitors 5 (8.2) 2 (5.6) 3 (12.0)
Angiotensin II receptor
blockers
16 (26.2) 11 (30.5) 5 (20.0)
Calcium channel blockers 26 (42.6) 18 (50.0) 8 (32.0)
a blockers 4 (6.6) 4 (11.1) 0 (0)
b blockers 7 (11.5) 4 (11.1) 3 (12.0)
Diuretics 13 (21.3) 8 (22.2) 5 (20.0)
Statins 8 (13.1) 4 (11.1) 4 (16.0)
Total protein (g/l) 6.460.1 6.460.1 6.460.1
BUN (mg/dl) 63.462.4 62.463.1 64.963.8
Cr (mg/dl) 10.160.3 9.760.4 10.660.5
K (mEq/l) 5.360.1 5.260.1 5.560.2
Total cholesterol (mg/dl) 168.664.7 159.465.9 181.767.0*
HDL cholesterol (mg/dl) 40.961.7 43.562.2 37.262.6
LDL cholesterol (mg/dl) 101.563.6 96.264.6 109.465.6
Triglycerides (mg/dl) 112.567.2 90.268.2 142.769.7**
Blood glucose (mg/dl) 124.766.4 115.468.2 137.569.7
Insulin (mU/ml) 20.462.4 15.763.1 27.063.6*
HbA1c (%) 5.460.2 5.260.3 5.660.3
C-reactive protein (mg/dl) 0.4560.08 0.4460.10 0.4760.12
Adiponectin (mg/ml) 17.761.0 19.561.3 15.061.6*
Variables are expressed as means6SEM or number (%).
*P ,0.05 vs. Low-FABP4.
**P ,0.01 vs. Low-FABP4.
doi:10.1371/journal.pone.0027356.t003
Table 4. Cox proportional hazard model for prognosis at 7
year follow-up.
HR 95% CI p
Age 1.054 1.005 – 1.117 0.029
Gender (Male) 2.447 0.715 – 9.177 0.153
Diabetes mellitus 1.198 0.317 – 4.390 0.783
HD duration 0.993 0.978 – 1.006 0.293
Body mass index 0.866 0.678 – 1.079 0.209
log Triglycerides 0.881 0.135 – 6.511 0.898
log FABP4 7.751 1.052 – 25.316 0.044
doi:10.1371/journal.pone.0027356.t004
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